Benzinga · Oct 12, 2026
Needham Maintains Buy on Enovis, Lowers Price Target to $34
Needham analyst Mike Matson maintains Enovis (NYSE:ENOV) with a Buy and lowers the price target from $52 to $34.
EN
NYSE · ENOV
Enovis Corporation
Industrials · Industrial - Machinery
$19.87
Up+$0.82 (+4.13%)
Updated Oct 20, 2026, 10:37 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.59B
- P/E ratio
- -1.17
- Dividend yield
- 0.00%
- 52-week range
- $16.70 – $31.67
- Volume
- 1.62M
- Avg. volume
- 806.57K
Price performance · ENOV
ENOV price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 19, 2026
ENOV closed at $19.87 after 21 trading sessions, up 10.14% for the selected period.
- Last close
- $19.87
- Period change
- +10.14%
- Period low
- $17.43
- Period high
- $19.87
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | $19.53 | $20.15 | $19.43 | $19.87 | 1.62M |
| Oct 16, 2026 | $19.64 | $19.78 | $19.36 | $19.59 | 1.45M |
| Oct 15, 2026 | $18.76 | $19.44 | $18.42 | $19.35 | 1.29M |
| Oct 14, 2026 | $18.74 | $18.85 | $18.235 | $18.57 | 1.14M |
| Oct 13, 2026 | $18.50 | $19.12 | $18.175 | $18.99 | 1.41M |
| Oct 12, 2026 | $17.47 | $18.40 | $17.36 | $18.25 | 910.92K |
| Oct 9, 2026 | $17.60 | $17.89 | $17.145 | $17.69 | 1.15M |
| Oct 8, 2026 | $17.35 | $17.63 | $16.70 | $17.43 | 2.31M |
| Oct 7, 2026 | $18.03 | $18.13 | $17.53 | $17.61 | 1.29M |
| Oct 6, 2026 | $19.01 | $19.01 | $18.055 | $18.20 | 1.02M |
| Oct 5, 2026 | $17.70 | $18.96 | $17.56 | $18.69 | 1.36M |
| Oct 2, 2026 | $18.27 | $18.27 | $17.675 | $17.77 | 1.37M |
| Oct 1, 2026 | $18.19 | $18.51 | $17.74 | $18.05 | 1.59M |
| Sep 30, 2026 | $18.51 | $18.70 | $18.08 | $18.27 | 1.94M |
| Sep 29, 2026 | $18.00 | $18.63 | $17.88 | $18.46 | 1.53M |
| Sep 28, 2026 | $18.28 | $18.46 | $17.97 | $18.16 | 1.47M |
| Sep 25, 2026 | $18.31 | $18.79 | $18.06 | $18.46 | 1.29M |
| Sep 24, 2026 | $18.32 | $18.50 | $17.675 | $18.27 | 1.72M |
| Sep 23, 2026 | $18.29 | $18.5615 | $17.86 | $18.24 | 1.18M |
| Sep 22, 2026 | $18.45 | $18.65 | $18.125 | $18.39 | 1.79M |
| Sep 21, 2026 | $18.18 | $18.18 | $17.48 | $18.04 | 2.59M |
Latest ENOV news
The latest Smart Investors Daily articles mentioning ENOV.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ENOV research
Overview
Company profile and research snapshot.
Company profile
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $64.50
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | Needham | Buy | — |
| Sep 2, 2026 | Wells Fargo | Overweight | — |
| Sep 2, 2026 | Citizens | Market Outperform | — |
| Sep 2, 2026 | Freedom Capital Markets | Buy | — |
| Sep 2, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 10, 2026
Enovis (ENOV), Why Is Fresh Attention Building Now?
Upcoming earnings call puts Enovis in focus Enovis (ENOV) has scheduled an investor conference call and webcast for November 5, 2026 to review its third quarter results, giving shareholders fresh information on operations, profitability, and recent share performance. Recent trading has been weak for Enovis, with the share price down 31.3% over the past 90 days and 33.3% year to date, and the 1 year total shareholder return down 40.4%. This suggests sentiment has cooled despite a small 1 day...
Yahoo · Oct 10, 2026
Is Enovis (ENOV) Stock Cheap After Reaffirming 2026 Guidance?
Enovis has seen its share price come under pressure in recent years, and that drop puts a spotlight on a simple question for investors who care about fundamentals. Do the cash flows that Enovis can generate over time line up with where the stock trades today? Over the past 5 years the share price has fallen 79.7%, which puts the focus squarely on whether the current valuation still reflects the cash the business can produce. Recent updates pointed to mid single digit organic sales growth and...
Yahoo · Oct 8, 2026
Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
Dallas, TX, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2026 financial results on Thursday, November 5th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
